Sun D, et al. - Experts conducted a meta-analysis to assess the safety and effectiveness of apatinib (a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2). Results of this study suggested that good disease control was seen in patients treated with apatinib. The data presented showed a higher dose of apatinib significantly increased the objective response rate in lung and breast cancer and disease control rate in liver and gastric cancer. Hypertension, hand-foot syndrome, and proteinuria were the most common grade 3–4 adverse events seen. It was concluded that, for solid tumors, apatinib is a novel VEGFR-2 inhibitor with proven safety and effectiveness and a broad-spectrum anticancer effect.